Catterton Tries Its Luck On "Stretch-Mark Cream Turned Anti-Wrinkle Phenom"
This article was originally published in The Rose Sheet
Executive Summary
Private equity firm Catterton Partners augments its cosmeceutical portfolio with the acquisition of an early trailblazer across the cosmetics/pharmaceuticals frontier, StriVectin
You may also be interested in...
Crown To Acquire StriVectin, Appoint Its President Chief Commercial Officer
StriVectin president Cori Aleardi will join Crown’s executive leadership team, helping to merge the businesses and drive growth across Crown’s brand portfolio, which includes PanOxyl acne wash, Blue Lizard Australian Sunscreen, the SkinPen microneedling device, and prescription skin creams.
StriVectin’s #FightTechNeck Campaign Could Draw Millennials To Anti-Aging
Prestige skin-care brand is positioning a range of StriVectin offerings as preventative against “tech neck,” or signs of aging that result from the repeated strain of checking mobile devices throughout the day. A comprehensive marketing campaign kicks off this fall with the potential to make anti-aging a more relevant category among Millennials.
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.